IN OTHER WORDS...

By Oren Rawls

Published December 12, 2003, issue of December 12, 2003.
  • Print
  • Share Share

Prescription for Disaster: “While much of the nation has been following the deliberations in Congress over a Medicare drug benefit, a quiet revolution has been taking place in the way benefits are managed for the 200 million Americans who already have insurance for prescription drugs,” Cindy Parks Thomas announces in the December 4 issue of the venerable New England Journal of Medicine.

Gone, at least for the most part, are the days when those with insurance simply forked over a $5 co-payment to “take two and call me in the morning.” Today, nearly two-thirds of prescription drug plans have adopted “three-tier formularies,” under which enrollees usually pay $10 for generic drugs, $15 for preferred or low-cost brand-name drugs and $25 or more for non-preferred or expensive brand-name drugs.

In theory, incentive-based formularies encourage the insured to opt for lower-cost prescription drugs, cutting costs for health care plans that can then be passed on to the consumer. The only problem with the theory, writes Thomas, co-director of the Prescription Drug Analysis Group at Brandeis University’s Schneider Institute for Health Policy, is that it’s bunk.

“Researchers consistently report that regardless of the particular details, incentive-based formularies lead to higher out-of-pocket costs to consumers and to some patients’ going without prescription drugs,” she asserts. “The extent to which total savings are passed on to employers or consumers are largely unknown and remain highly guarded industry secrets.”

Thomas’s claim is backed up by research conducted by a team of health care professionals led by Haiden Huskamp, an assistant professor of health economics at Harvard Medical School; his team’s findings are presented in a separate article in the same issue. The article examines the effects of incentive-based formularies on prescription-drug utilization and spending. The authors draw cautionary conclusions that stand in marked contrast to the unabashed optimism with which President Bush this week signed into law legislation giving the elderly prescription drug coverage under Medicare.

“Different changes in formulary administration may have dramatically different effects on utilization and spending and may in some instances lead enrollees to discontinue therapy,” warns Huskamp. “The associated changes in copayments can substantially alter out-of-pocket spending by enrollees, the continuation of the use of medications and possibly the quality of care.”

Huskamp and his team found that when companies switched to a three-tier prescription drug plan, some workers simply stopped filling their prescriptions. Such formularies, the researchers found, particularly affected those with lower incomes or chronic diseases.

“When patients either switch medications or discontinue therapy, are they merely skipping therapy of marginal value, or are they forgoing treatment that is medically necessary?” Thomas asks. “The patient must determine which medications are crucial.”

A growing number of patients, according to a third article in the New England Journal of Medicine, have already determined that their health is too valuable to be left in the hands of the American pharmaceutical industry.

“In a grass-roots movement that has swelled to a stampede over the past several years, U.S. citizens are heading to Canada to buy cheaper prescription drugs,” reports Dr. Abigail Zuger, a correspondent for the medical journal. “They are crossing the border in person, by telephone, by fax and by modem, in numbers estimated at a million or more.”

According to research by Canada’s federal Patented Medicine Prices Review Board, prices of patented prescription drugs are, on average, 67% higher in the United States than in Canada. America’s neighbor to the north ties prices for new medications not only to the going rate for drugs already on the market, but also to the cost of other consumer goods.

Doctors fielding questions from patients about the legality and safety of filling prescriptions through Canadian outlets, Zuger cautions, may find themselves at a loss for answers. Health care providers are likely to face similar dilemmas concerning queries over incentive-based formularies, particularly in regard to Bush’s recently passed overhaul of Medicare. What is clear to many, though, is that the American health care system is sick — and in need of a second opinion.

“When it comes to efforts to understand the effect of formulary design on the utilization of and spending on drugs, the devil is in the details,” Huskamp diagnoses. “As three-tier formularies become increasingly prevalent, we need much greater knowledge about these details in order to reap the advantages in cost savings without causing deleterious consequences for patients.”






Find us on Facebook!
  • "I’ve never bought illegal drugs, but I imagine a small-time drug deal to feel a bit like buying hummus underground in Brooklyn."
  • We try to show things that get less exposed to the public here. We don’t look to document things that are nice or that people would like. We don’t try to show this place as a beautiful place.”
  • A new Gallup poll shows that only 25% of Americans under 35 support the war in #Gaza. Does this statistic worry you?
  • “You will stomp us into the dirt,” is how her mother responded to Anya Ulinich’s new tragicomic graphic novel. Paul Berger has a more open view of ‘Lena Finkle’s Magic Barrel." What do you think?
  • PHOTOS: Hundreds of protesters marched through lower Manhattan yesterday demanding an end to American support for Israel’s operation in #Gaza.
  • Does #Hamas have to lose for there to be peace? Read the latest analysis by J.J. Goldberg.
  • This is what the rockets over Israel and Gaza look like from space:
  • "Israel should not let captives languish or corpses rot. It should do everything in its power to recover people and bodies. Jewish law places a premium on pidyon shvuyim, “the redemption of captives,” and proper burial. But not when the price will lead to more death and more kidnappings." Do you agree?
  • Slate.com's Allison Benedikt wrote that Taglit-Birthright Israel is partly to blame for the death of American IDF volunteer Max Steinberg. This is why she's wrong:
  • Israeli soldiers want you to buy them socks. And snacks. And backpacks. And underwear. And pizza. So claim dozens of fundraising campaigns launched by American Jewish and Israeli charities since the start of the current wave of crisis and conflict in Israel and Gaza.
  • The sign reads: “Dogs are allowed in this establishment but Zionists are not under any circumstances.”
  • Is Twitter Israel's new worst enemy?
  • More than 50 former Israeli soldiers have refused to serve in the current ground operation in #Gaza.
  • "My wife and I are both half-Jewish. Both of us very much felt and feel American first and Jewish second. We are currently debating whether we should send our daughter to a Jewish pre-K and kindergarten program or to a public one. Pros? Give her a Jewish community and identity that she could build on throughout her life. Cons? Costs a lot of money; She will enter school with the idea that being Jewish makes her different somehow instead of something that you do after or in addition to regular school. Maybe a Shabbat sing-along would be enough?"
  • Undeterred by the conflict, 24 Jews participated in the first ever Jewish National Fund— JDate singles trip to Israel. Translation: Jews age 30 to 45 travelled to Israel to get it on in the sun, with a side of hummus.
  • from-cache

Would you like to receive updates about new stories?




















We will not share your e-mail address or other personal information.

Already subscribed? Manage your subscription.